CUSIP: 81362J209
Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,575,574
-
Share change
-
+789,644
-
Total reported value
-
$5,826,000
-
Put/Call ratio
-
75%
-
Price per share
-
$1.63
-
Number of holders
-
26
-
Value change
-
+$530,657
-
Number of buys
-
16
-
Number of sells
-
17
Quarterly Holders Quick Answers
What is CUSIP 81362J209?
CUSIP 81362J209 identifies EYES - SECOND SIGHT MED PRODS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2022
-
Previous quarter:
Q3 2021
Recent filing periods for CUSIP 81362J209:
Institutional Holders of SECOND SIGHT MED PRODS INC - COM NEW (EYES) as of Q4 2021
As of 31 Dec 2021,
SECOND SIGHT MED PRODS INC - COM NEW (EYES) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,575,574 shares.
The largest 10 holders included
VANGUARD GROUP INC, MORGAN STANLEY, SABBY MANAGEMENT, LLC, SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC, GEODE CAPITAL MANAGEMENT, LLC, STATE STREET CORP, BlackRock Inc., CITADEL ADVISORS LLC, NORTHERN TRUST CORP, and Rafferty Asset Management, LLC.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.